CYDY CytoDyn

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City.

Robert E. Hoffman, Chief Financial Officer, will deliver a presentation on Wednesday, September 10, at 1:30 p.m. EDT, which will be accessible via webcast , and will be available for one-on-one meetings with registered conference attendees.

About CytoDyn

CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.

Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit and follow us on .

Investor Relations

CytoDyn Inc.

Media Contacts

Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.

Russo Partners, LLC



EN
28/08/2025

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Closes $17.5 Million Financing to Fund Continued Development o...

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $17.5 million in gross proceeds, with Paulson Investment Company acti...

19h / 38m 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Surviv...

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibod...

February 20, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Funding and Initiation of Expanded Access Program fo...

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

December 2025 Letter to Shareholders

December 2025 Letter to Shareholders VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your support, patience, and continued belief in CytoDyn’s (the “Company”) mission. I will remember 2025 as the year in which we first presented our astonishing survival observations and compelling data on the emerging role of leronlimab in solid tumor oncology. This past year has been one of disciplined execution, operational rebuilding, and meaningful scient...

December 16, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metast...

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with leronlimab in combination with or followed by an immune checkpoint inhibitor VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, ...

December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch